Vaginal drug distribution modeling

被引:44
作者
Katz, David F. [1 ,2 ]
Yuan, Andrew [1 ]
Gao, Yajing [1 ]
机构
[1] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA
[2] Duke Univ, Dept Obstet & Gynecol, Durham, NC USA
关键词
Vagina; Microbicides; HIV; Modeling; Mucosa; Gel; Ring; TOPICAL MICROBICIDES; ANTIBODY DELIVERY; HIV-INFECTION; TENOFOVIR GEL; TRANSPORT; TISSUE; DEPLOYMENT; PHARMACOKINETICS; PERCEPTIONS; FORMULATION;
D O I
10.1016/j.addr.2015.04.017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review presents and applies fundamental mass transport theory describing the diffusion and convection driven mass transport of drugs to the vaginal environment. It considers sources of variability in the predictions of the models. It illustrates use of model predictions of microbicide drug concentration distribution (pharmacokinetics) to gain insights about drug effectiveness in preventing HIV infection (pharmacodynamics). The modeling compares vaginal drug distributions after different gel dosage regimens, and it evaluates consequences of changes in gel viscosity due to aging. It compares vaginal mucosal concentration distributions of drugs delivered by gels vs. intravaginal rings. Finally, the modeling approach is used to compare vaginal drug distributions across species with differing vaginal dimensions. Deterministic models of drug mass transport into and throughout the vaginal environment can provide critical insights about the mechanisms and determinants of such transport. This knowledge, and the methodology that obtains it, can be applied and translated to multiple applications, involving the scientific underpinnings of vaginal drug distribution and the performance evaluation and design of products, and their dosage regimens, that achieve it. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:2 / 13
页数:12
相关论文
共 62 条
  • [1] Why consider vaginal drug administration?
    Alexander, NJ
    Baker, E
    Kaptein, M
    Karck, U
    Miller, L
    Zampaglione, E
    [J]. FERTILITY AND STERILITY, 2004, 82 (01) : 1 - 12
  • [2] [Anonymous], 2014, PHARMACEUTICS, V6
  • [3] Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
  • [4] Baseline dimensions of the human vagina
    Barnhart, Kurt T.
    Izquierdo, Adriana
    Pretorius, E. Scott
    Shera, David M.
    Shabbout, Mayadah
    Shaunik, Alka
    [J]. HUMAN REPRODUCTION, 2006, 21 (06) : 1618 - 1622
  • [5] NOVEL VAGINAL DRUG-RELEASE APPLICATIONS
    BRANNONPEPPAS, L
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1993, 11 (1-2) : 169 - 177
  • [6] Transport and Transport Properties of Tenofovir from Microbicide Gels into Vaginal Tissue: Analysis Using Raman Spectroscopy
    Chuchuen, Oranat
    Henderson, Marcus H.
    Sandros, Marinella G.
    Kashuba, Angela D. M.
    Katz, David F.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A59 - A60
  • [7] Quantitative Analysis of Microbicide Concentrations in Fluids, Gels and Tissues Using Confocal Raman Spectroscopy
    Chuchuen, Oranat
    Henderson, Marcus H.
    Sykes, Craig
    Kim, Min Sung
    Kashuba, Angela D. M.
    Katz, David F.
    [J]. PLOS ONE, 2013, 8 (12):
  • [8] das Neves J., 2014, DRUG DELIVERY DEV AN
  • [9] das Neves JJ., 2006, GELS VAGINAL DRUG DE, V318, P14
  • [10] INTERSPECIES SCALING OF REGIONAL DRUG DELIVERY
    DEDRICK, RL
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (11) : 1047 - 1052